UK markets close in 7 hours 11 minutes
  • FTSE 100

    7,571.23
    +15.00 (+0.20%)
     
  • FTSE 250

    19,416.41
    +53.13 (+0.27%)
     
  • AIM

    853.12
    -0.20 (-0.02%)
     
  • GBP/EUR

    1.1638
    -0.0022 (-0.19%)
     
  • GBP/USD

    1.2289
    -0.0007 (-0.06%)
     
  • BTC-GBP

    14,105.94
    +193.70 (+1.39%)
     
  • CMC Crypto 200

    411.22
    +9.79 (+2.44%)
     
  • S&P 500

    4,071.70
    -4.87 (-0.12%)
     
  • DOW

    34,429.88
    +34.88 (+0.10%)
     
  • CRUDE OIL

    80.99
    +1.01 (+1.26%)
     
  • GOLD FUTURES

    1,809.40
    -0.20 (-0.01%)
     
  • NIKKEI 225

    27,820.40
    +42.50 (+0.15%)
     
  • HANG SENG

    19,518.29
    +842.94 (+4.51%)
     
  • DAX

    14,496.20
    -33.19 (-0.23%)
     
  • CAC 40

    6,736.72
    -5.53 (-0.08%)
     

Affimed to Present at the 2022 Jefferies London Healthcare Conference

Affimed N.V.
Affimed N.V.

HEIDELBERG, Germany, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Dr. Adi Hoess, will present at the 2022 Jefferies London Healthcare Conference on Wednesday, November 16, 2022, at 12:55 p.m. GMT / 7:55 a.m. EST / 13:55 CET.

A live webcast of the presentation will be accessible on Affimed’s website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. A replay of the call will be archived on Affimed’s website for 30 days after the call.

For more information on the conference or to schedule a one-on-one meeting with Affimed management, please contact your Jefferies representative or Alex Fudukidis via email at a.fudukidis@affimed.com or phone at +1 (917) 436-8102.

About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to give patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s proprietary ROCK® platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs.
The ROCK® platform predictably generates customized innate cell engager (ICE®) molecules, which use patients’ immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE®. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.

Affimed Investor Contact
Alexander Fudukidis
Director, Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102